Vistagen Therapeutics, Inc.
VTGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001411685
No open-market purchases or sales by Vistagen Therapeutics, Inc. insiders were filed in the last 90 days; 48 institutions reported holding it in 13F filings for Q2 2026, worth $2.54M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Vistagen Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- +27 vs. Q1 2021
- Shares held
- 123.5M
- +17.6M (+16.6%) vs. Q1 2021
- Total value
- $389.0M
- +$163.8M (+72.7%) vs. Q1 2021
- New holders
- 46
- 23 more added
- Sold out
- 19
- 22 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VTGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 48 | $2.54M |
| Q1 2026 | 56 | $8.12M |
| Q4 2025 | 55 | $8.84M |
| Q3 2025 | 58 | $81.8M |
| Q2 2025 | 51 | $30.3M |
| Q1 2025 | 48 | $39.0M |
| Q4 2024 | 54 | $44.9M |
| Q3 2024 | 47 | $45.3M |
| Q2 2024 | 43 | $56.3M |
| Q1 2024 | 42 | $90.8M |
| Q4 2023 | 46 | $90.0M |
| Q3 2023 | 34 | $15.7M |
| Q2 2023 | 33 | $1.82M |
| Q1 2023 | 83 | $4.79M |
| Q4 2022 | 86 | $4.15M |
| Q3 2022 | 93 | $9.13M |
| Q2 2022 | 112 | $122.1M |
| Q1 2022 | 116 | $167.8M |
| Q4 2021 | 106 | $269.2M |
| Q3 2021 | 105 | $360.2M |
| Q2 2021 | 101 | $389.0M |
| Q1 2021 | 74 | $225.2M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Vistagen Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 16,302,596 | $51.4M | 0.67% | 00.0% | Unchanged |
| Marshall Wace North America L.P. | 0 | $0 | 0.00% | −2,828,450−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −1,062,252−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −321,072−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −167,466−100.0% | Sold out |
| Capstone Investment Advisors, LLC | 0 | $0 | 0.00% | −125,148−100.0% | Sold out |
| LMR Partners LLP | 0 | $0 | 0.00% | −84,775−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −62,124−100.0% | Sold out |
| Jefferies Group LLC | 0 | $0 | 0.00% | −28,900−100.0% | Sold out |
| Financial Advocates Investment Management | 0 | $0 | 0.00% | −23,097−100.0% | Sold out |
| GWM Advisors LLC | 0 | $0 | 0.00% | −22,300−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −19,179−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −12,897−100.0% | Sold out |
| First Republic Investment Management, Inc. | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Sciencast Management LP | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| International Assets Investment Management, LLC | 0 | $0 | 0.00% | −2,750−100.0% | Sold out |
| Wells Fargo & Company | 0 | $0 | 0.00% | −863−100.0% | Sold out |
| NVWM, LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Burleson & Company, LLC | 0 | $0 | 0.00% | −350−100.0% | Sold out |
| Harel Insurance Investments & Financial Services Ltd. | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |